WA-VIRTUOZZO
15.3.2022 12:02:04 CET | Business Wire | Press release
Virtuozzo , the alternative cloud platform leader, announced today that it will preview at CloudFest 2022 two never-before-seen solutions designed to help service providers bring to market modern cloud-based solutions that answer long-ignored market needs. The products are the PaaS-focused Virtuozzo Application Platform for WordPress and Virtuozzo Hybrid Server Lite. Framing their value proposition, Virtuozzo executives will deliver two keynote presentations outlining the current industry trends and landscape shaping the need for those services. The sessions will also introduce practical strategies for service providers to integrate and deploy the new solutions in ways that help them increase competitive positioning while growing their business.
Attendees can visit Virtuozzo, a platinum event sponsor, at Stand C01 throughout the show (March 22 – 24) in Europa-Park, Germany. Additionally, a special on-site promotion will give service providers six months free licensing for key solutions showcased during the conference.
Virtuozzo: Bringing Cloud to All
As a company, Virtuozzo has strategically evolved over the last several years to fill a polarizing void in the cloud enablement market. The most common paths to the cloud leverage hyperscaler or enterprise-centric platforms that are generally inflexible, cost-prohibitive, and too complex for non-specialized end users to manage. This puts many businesses, particularly small- to medium-sized ones, at a disadvantage. Which is where Virtuozzo comes in.
“There was an inherent promise in the beginning that cloud would be easy. Accessible to all. In reality, that is not how things panned out,” said Alex Fine, CEO, Virtuozzo. “Virtuozzo is solving that problem through collaborative partnerships with service providers that empower them to become full-service, alternative cloud providers.”
Virtuozzo develops and delivers the most comprehensive cloud platform stack purpose built for service providers. That infrastructure allows services providers to quickly carve out a wide portfolio of cloud services that are easy to use, easy to manage, and easy to scale. This frees them to then focus on areas where they can strongly differentiate, from the delivery of unique products and skills to high-touch customer support.
Virtuozzo Keynote Presentations
The Service Provider Landscape in 2022: Where is the Low-Hanging Fruit?
March 22 at 3:45 PM CET
Carlos Rego, Virtuozzo’s VP of Strategic Development, addresses the roller coaster ride that has been the experience of hosters, MSPs and cloud providers over the past decade. He provides expert perspective on the complex landscape they currently operate in, how the industry is evolving, and how these service providers can strategically grow their businesses without overly taxing their operations.
WordPress Hosting? It’s Time to Grow Up.
March 23 at 4:40 PM CET
In his second presentation, Carlos Rego will introduce viable revenue-generating opportunities surrounding the booming $500B+ WordPress economy. With new PaaS capabilities via Virtuozzo Application Platform for WordPress targeting business-critical WordPress sites, service providers can strengthen their businesses while helping modernize an enormous ecosystem that can be argued is antiquated today.
Schedule a Meeting
To meet with a Virtuozzo team member on site, contact info@Virtuozzo.com .
About Virtuozzo
Virtuozzo (www.virtuozzo.com ) provides the leading alternative cloud platform for service providers, enabling them to sell cloud services that are more accessible, more affordable and easier to use than hyperscaler solutions. The company’s legacy includes developing the first commercially available container technology and being a major contributor to numerous virtualization and open-source projects for more than 20 years. Today, Virtuozzo cloud solutions are used by more than 700 Cloud Service Providers, Managed Service Providers and Hosting Providers in 80 countries. Virtuozzo is based in Schaffhausen, Switzerland, and has more than 320 employees across the U.S., UK, Europe, and Asia-Pacific.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005472/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom